abstract: Role of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Focal and Generalized Infectious and Inflammatory Disorders

Role of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Focal and Generalized Infectious and Inflammatory Disorders

Abstract

"Several advances in imaging have become part of the work-up for localization, diagnosis, and management of infectious diseases and inflammatory disorders. Utility of multiple imaging modalities is a time-consuming step, and significant numbers of patients remain undiagnosed despite utilization of series of tests. Inflammatory cells have avidity for fluorine 18–labeled fluorodeoxyglucose (¹⁸F-FDG), and thus positron emission tomographic–computed tomographic (PET-CT) hybrid imaging provides anatomical and metabolic information that can be used to define the extent of infectious and inflammatory diseases and assess response to treatment. PET-CT provides a “one-stop test” in which use of hybrid imaging provides anatomical and metabolic information. The extent of disease is defined quickly, and response to treatment can be assessed. This modality also helps define the metastatic and/or septic foci where there is lack of localizing symptoms. More recently, there is increasing awareness among clinicians regarding the ability of PET-CT to help in diagnosing, characterizing, and assessing inflammatory disorders. This article reviews the usefulness of this imaging modality."

Feb 27th: PET Report | TRIUMF : Canada's National Laboratory for Particle and Nuclear Physics (PET/CT scans)

"There is a human element to be considered in determining the value of a PET scan: The present report identifies numerous healthcare policies and provides considerable statistical information to describe the impact of PET imaging on cancer treatment. But it is also important to note that the impact of any healthcare policy goes beyond statistics to have a direct impact on individual patients and their families."

 
PET Report

The Use of Positron Emission Tomography (PET) for Cancer Across Canada: Time for a National Strategy

On Monday, February 27, 2012, TRIUMF/AAPS released a report surveying the utilization of PET imaging technolgoy for clincial care of cancer across Canada. The full report is available here in PDF format (about 3 MB). Susan Martinuk's briefing slides are available here. Helen Branswell's coverage on CTV.ca via the Canadian Press Pamela Fayerman's coverage in the Vancouver Sun

Cancer is a growing challenge to Canadians and an increasing burden on healthcare budgets. A ground-breaking report released today suggests that access to, and utilization of, leading-edge medical-imaging technology for the diagnosis, staging, and monitoring of cancer treatment varies widely from province to province, putting cancer patients in some areas at a distinct disadvantage.
The technology, called Positron Emission Tomography, is often coupled with Computerized Tomography (CT) and is known as PET/CT imaging. PET imaging is already widely used and integral to cancer care in most developed nations, and increased utilization of this technology could provide more clinically-effective and cost-effective treatment for cancer patients in Canada. A nationally coordinated strategy to take up this technology and standardize its use could bring Canada back to the forefront of global cancer care.

"Canada conducted 42,620 scans in 2009; 22,400 (51%) of those were carried out in the province of Quebec."

(PDF) Table of Contents

1.0 Summary of Key Findings....................................................................................................3
2.0 Preface ................................................................................................................................7
3.0 Executive Summary............................................................................................................11
4.0 Introduction to Positron Emission Tomography (PET)........................................................23
5.0 Clinical Effectiveness of PET Imaging in Oncology............................................................33
6.0 Cost Effectiveness..............................................................................................................43
7.0 Status of PET Imaging in Canada.......................................................................................47
8.0 Status of PET Imaging in British Columbia.......................................................................61
9.0 Status of PET Imaging in Alberta.......................................................................................69
10.0 Status of PET Imaging in Saskatchewan...........................................................................77
11.0 Status of PET Imaging in Manitoba....................................................................................83
12.0 Status of PET Imaging in Ontario.......................................................................................89
13.0 Status of PET Imaging in Quebec..................................................................................... 103
14.0 Status of PET Imaging in Nova Scotia ............................................................................. 113
15.0 Status of PET Imaging in New Brunswick....................................................................... 119
16.0 Status of PET Imaging in Prince Edward Island.............................................................. 125
17.0 Status of PET Imaging in Newfoundland......................................................................... 131

18.0 Findings: An Opportunity to Improve the Cancer Care of Canadians............................. 137

19.0 Conclusions: Time for a National Strategy...................................................................... 149

Picture this: The new imaging techniques that can help doctors select the right treatment at the right time - Cutting Edge - Cancer World (eg. MRI/PET/CT/therapies/biomarkers....)

Blogger's Note: worth reading

PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis 10.1016/j.critrevonc.2011.10.002 : Critical Reviews in Oncology

  A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings.

At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes.. ...

Highlights

► FDG-PET/CT is a valid instrument for the detection of recurrent or metastatic gynaecologic tumours.
► Evidence corroborates FDG-PET/CT's role in ovarian cancer in monitoring response to chemotherapy.
► In uterine cervical carcinoma, FDG-PET/CT is more sensitive than MRI for detecting nodal metastases.
► Retrospective analysis of 116 patients showed FDG-PET/CT was principally useful in the setting of suspected recurrence.

Impact of F-18 fluorodeoxyglucose positron emission tomography-computed tomography on oncologic patient management: British Columbia (abstract)

"..The results of the PET-CT study resulted in a change in treatment decision in 49.8% of the studies and resulted in improved decision making in 83.2% of the studies."